Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency - Full Text View

Purpose

The purpose of this study is to gather more information about the safety of ACZONE Gel, 5% in treating subjects with acne who have certain blood disorders.

ACZONE Gel, 5% is a prescription skin use (topical) medicine used to help treat acne in people 12 years and older. ACZONE Gel, 5% has been studied in approximately 4000 people and was shown to reduce the number of pimples and improve acne.

The active drug ingredient in ACZONE Gel, 5% is dapsone. People with blood disorders called "G6PD deficiency", "methemoglobin reductase deficiency", and "hemoglobin M" have a higher chance of side effects with dapsone.

G6PD is short for "glucose-6-phosphate dehydrogenase". It is an enzyme found in red blood cells, which carry oxygen to all parts of the body. G6PD helps the red blood cells to function normally. Some people have less G6PD in their red blood cells than the average person. This is called G6PD deficiency.

Two treatments - ACZONE Gel, 5% and placebo - will be studied for comparison.

Condition	Intervention	Phase
Acne Vulgaris	Drug: ACZONE Gel, 5% Drug: Vehicle	Phase IV

Genetics Home Reference related topics:

glucose-6-phosphate dehydrogenase deficiency

MedlinePlus related topics:

Acne

ChemIDplus related topics:

Dapsone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety Study

Official Title:	ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%.

Further study details as provided by Allergan:

Primary Outcome Measures:

The within-subject between treatment period differences in change from baseline to the 2nd week of each treatment period and change from baseline to the end of each treatment period will be summarized based upon various lab parameters.
The safety evaluable data set will be used, and each variable will be summarized using descriptive statistics.
Analyses of clinical lab values, AEs, vitals, and concomitant meds will be performed on all subjects who received treatment.

Secondary Outcome Measures:

Acne Lesions: Tabular summaries of total lesion counts will be provided by appropriate descriptive statistics.

Estimated Enrollment:	60
Study Start Date:	October 2005
Estimated Study Completion Date:	October 2006

Detailed Description:

Study Objectives:

To compare the safety profile and risk of hemolysis of ACZONE Gel, 5% to that of the vehicle after 12 weeks each of twice daily applications in acne vulgaris subjects with glucose-6-phosphate-dehydrogenase (G6PD) deficiency.
To determine the systemic levels of plasma dapsone and N-acetyl dapsone during treatment with ACZONE Gel, 5%.

Study Population:

Approximately 60 male and female subjects

Study Treatment:

All subjects in the study will receive ACZONE Gel, 5% and vehicle in 1 of 2 sequences; each for a 12-week period.

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

To be eligible for this study, subjects must fulfill all of the following criteria:

Male or female ≥12 years of age.
A clear diagnosis of acne vulgaris, defined as ≥20 acne inflammatory and/or non-inflammatory lesions (≥10 of the acne lesions must be on the face, the others may be present on the neck, shoulders, upper chest, and upper back) at screening.
A diagnosis of G6PD deficiency, defined as having a G6PD value below the lower limit of normal for the central reference laboratory.

Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from the study:

A dermal examination reveals the presence of severe cystic acne or acne conglobata.
Treatment with isotretinoin (Accutane®) within 3 months of baseline and throughout the study.
Subjects predisposed to anemia for other medical reasons, including but not limited to gastrointestinal bleeding and cancer.
Subjects who are using topical or systemic medications for acne throughout the study. This includes, but is not limited to, benzoyl peroxide, antibiotics, topical Vitamin A derivatives such as Retin-A.
Subjects who are using medication or eating foods that could potentially cause a hemolytic event in individuals with G6PD deficiency during the study.
Facial surgery (dermabrasion, laser resurfacing or other facial cosmetic surgeries) within 3 months of baseline and throughout the study.
A history of hypersensitivity to dapsone, parabens, or any component of the study products.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00243542

Show 29 Study Locations

Sponsors and Collaborators

Allergan

Investigators


Study Director:	Steven Garrett, MS, DDS	QLT USA, Inc.

More Information

Study ID Numbers:	ACZ ACN 01
First Received:	October 21, 2005
Last Updated:	September 8, 2008
ClinicalTrials.gov Identifier:	NCT00243542
Health Authority:	United States: Food and Drug Administration